Skip to content

GREAT POINT PARTNERS LLC

Follow

13F filer, CIK 1281446, Greenwich, CT

GREAT POINT PARTNERS LLC reported $418,469,943 across 45 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 51.11% of the portfolio.

Accepted , ingested 13F-HR 0001172661-26-005345

Period
2026-09-30
Reported value
$418M
Holdings
45
Top 10 weight
51.11%
New
12
Sold out
9

Part of the filer group GREAT POINT PARTNERS LLC

  • Dr. Jeffrey R. Jay, M.D.
  • Ms. Lillian Nordahl
How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • LONA LEONABIO INC: 13G 474,345 shares, 5.03% of the class, 13G filed 2026-11-04, 0001172661-26-004856Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IONSnew+420,000$18.8M
GMABnew+525,000$18.7M
BLTEnew+75,000$12.7M
ABCLnew+600,000$8.75M
VERAadded+207,881$6.71M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ALMSexited-856,061-$24.1M
ORKAreduced-158,681-$13.2M
IMMXexited-1,277,642-$13.2M
VORreduced-573,090-$10.9M
CTNMreduced-735,298-$9.87M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001172661-26-005345, largest first. % of portfolio is the value over $380,946,812, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 199,348 shares; 2026Q2: 600,836 shares; 2026Q3: 808,717 shares 808,717$26.1M6.85%+207,881Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,370,107 shares; 2026Q1: 1,750,000 shares; 2026Q2: 1,700,000 shares; 2026Q3: 1,126,910 shares 1,126,910$21.5M5.64%-573,090Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 1,811,996 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,700,000 shares; 2025Q4: 1,750,000 shares; 2026Q1: 1,750,000 shares; 2026Q2: 700,000 shares; 2026Q3: 700,000 shares 700,000$20.4M5.35%0Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,029,933 shares; 2026Q3: 1,961,701 shares 1,961,701$19.4M5.09%-68,232Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 425,000 shares; 2026Q3: 508,735 shares 508,735$19.4M5.08%+83,735Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 505,007 shares; 2025Q1: 250,000 shares; 2025Q2: 500,000 shares; 2025Q3: 80,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 420,000 shares 420,000$18.8M4.92%newTimeline
GMABGENMAB A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 525,000 shares 525,000$18.7M4.92%newTimeline
SLGLSOL-GEL TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 274,363 shares; 2026Q2: 274,363 shares; 2026Q3: 239,159 shares 239,159$17.8M4.66%-35,204Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,170,194 shares; 2025Q1: 3,170,194 shares; 2025Q2: 3,170,194 shares; 2025Q3: 3,815,930 shares; 2025Q4: 3,815,930 shares; 2026Q1: 4,215,930 shares; 2026Q2: 4,215,930 shares; 2026Q3: 4,077,256 shares 4,077,256$17M4.45%-138,674Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 300,000 shares; 2026Q2: 317,221 shares; 2026Q3: 410,420 shares 410,420$15.8M4.13%+93,199Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,648,523 shares; 2025Q1: 1,638,111 shares; 2025Q2: 1,291,617 shares; 2025Q3: 150,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 204,314 shares; 2026Q3: 155,000 shares 155,000$15.3M4.03%-49,314Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,500,000 shares; 2026Q2: 3,500,000 shares; 2026Q3: 3,500,000 shares 3,500,000$14.8M3.89%0Timeline
BLTEBELITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 75,000 shares 75,000$12.7M3.34%newTimeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,200,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 1,200,000 shares; 2026Q2: 1,200,000 shares; 2026Q3: 1,200,000 shares 1,200,000$10.9M2.87%0Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 210,732 shares; 2026Q1: 316,453 shares; 2026Q2: 175,000 shares; 2026Q3: 175,000 shares 175,000$10.6M2.78%0Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares; 2026Q2: 855,813 shares; 2026Q3: 855,813 shares 855,813$10M2.63%0Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 979,534 shares; 2026Q1: 1,334,130 shares; 2026Q2: 1,000,000 shares; 2026Q3: 800,000 shares 800,000$9.18M2.41%-200,000Timeline
ABCLABCELLERA BIOLOGICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 600,000 shares 600,000$8.75M2.3%newTimeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 442,761 shares; 2025Q1: 470,964 shares; 2025Q2: 485,859 shares; 2025Q3: 446,814 shares; 2025Q4: 350,000 shares; 2026Q1: 500,000 shares; 2026Q2: 352,180 shares; 2026Q3: 300,000 shares 300,000$8.35M2.19%-52,180Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$6.22M1.63%newTimeline
JATTJATT II ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 500,000 shares; 2026Q3: 500,000 shares 500,000$5.62M1.48%0Timeline
IFRXINFLARX NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,046,557 shares; 2026Q3: 3,046,557 shares 3,046,557$5.48M1.44%0Timeline
RACCRESEARCH ALLIANCE CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 504,891 shares 504,891$5.47M1.44%newTimeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 220,000 shares; 2026Q2: 109,603 shares; 2026Q3: 109,603 shares 109,603$5.46M1.43%0Timeline
AMANAMANAT ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 500,000 shares; 2026Q3: 500,000 shares 500,000$5.34M1.4%0Timeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,741,232 shares; 2026Q3: 1,741,232 shares 1,741,232$4.98M1.31%0Timeline
JTTTJATT III ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 450,000 shares 450,000$4.96M1.3%newTimeline
SCYXSCYNEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 944,292 shares; 2026Q3: 944,292 shares 944,292$4.66M1.22%0Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 634,032 shares; 2026Q1: 300,000 shares; 2026Q2: 300,000 shares; 2026Q3: 300,000 shares 300,000$4.61M1.21%0Timeline
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 320,952 shares 320,952$3.94M1.04%newTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 621,894 shares; 2025Q1: 833,042 shares; 2025Q2: 3,033,462 shares; 2025Q3: 2,451,809 shares; 2025Q4: 951,809 shares; 2026Q1: 951,809 shares; 2026Q2: 951,809 shares; 2026Q3: 951,809 shares 951,809$3.94M1.03%0Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 324,340 shares; 2026Q2: 1,970,187 shares; 2026Q3: 776,881 shares 776,881$3.76M0.99%-1,193,306Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 70,000 shares; 2026Q3: 70,000 shares 70,000$3.21M0.84%0Timeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 842,106 shares; 2026Q2: 842,106 shares; 2026Q3: 842,106 shares 842,106$3.17M0.83%0Timeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 374,679 shares; 2025Q3: 378,594 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 156,906 shares; 2026Q3: 250,000 shares 250,000$2.94M0.77%+93,094Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 325,000 shares; 2026Q1: 325,000 shares; 2026Q2: 325,000 shares; 2026Q3: 325,000 shares 325,000$2.68M0.7%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 800,000 shares; 2026Q1: 800,198 shares; 2026Q2: 921,481 shares; 2026Q3: 186,183 shares 186,183$2.5M0.66%-735,298Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 228,803 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 183,330 shares; 2025Q4: 183,330 shares; 2026Q1: 183,330 shares; 2026Q2: 183,330 shares; 2026Q3: 24,649 shares 24,649$2.05M0.54%-158,681Timeline
HUMAHUMACYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,750,000 shares; 2026Q2: 3,750,000 shares; 2026Q3: 3,750,000 shares 3,750,000$1.94M0.51%0Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,575,000 shares; 2026Q3: 1,663,144 shares 1,663,144$1.34M0.35%-911,856Timeline
RACDRESEARCH ALLIANCE CORP IVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 106,396 shares 106,396$1.28M0.34%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
IBRXIMMUNITYBIO INC COMput3,000,800$28.3M0
PHVSPHARVARIS N V COMMON STOCKput150,000$4.76Mnew
CTNMCONTINEUM THERAPEUTICS INC Stockcall300,000$4.03Mnew
ANNXANNEXON INC COMcall97,300$412Knew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ABVXABIVAX SA400,000$53.3Mcall
ALMSALUMIS INC856,061$24.1Mshares
RAREULTRAGENYX PHARMACEUTICAL IN600,000$20Mput
IMMXIMMIX BIOPHARMA INC1,277,642$13.2Mshares
SLNSILENCE THERAPEUTICS PLC450,000$4.94Mshares
PALIPALISADE BIO INC2,284,819$4.78Mshares
GALTGALECTIN THERAPEUTICS INC800,000$3.71Mcall
AVXLANAVEX LIFE SCIENCES CORP521,300$1.35Mcall
PMNPROMIS NEUROSCIENCES INC86,150$1.13Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-005345 base2026-11-16